[HTML][HTML] Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
…, A Claperon, F Rocchetti, A Zichi, L Kraus-Berthier… - Leukemia, 2019 - nature.com
Improving outcomes in acute myeloid leukemia (AML) remains a major clinical challenge.
Overexpression of pro-survival BCL-2 family members rendering transformed cells resistant to …
Overexpression of pro-survival BCL-2 family members rendering transformed cells resistant to …
The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression
…, P Finetti, E Josselin, H Lelièvre, L Kraus-Berthier… - Clinical cancer …, 2013 - AACR
Purpose: Cancer stem cells (CSC) are the tumorigenic cell population that has been shown
to sustain tumor growth and to resist conventional therapies. The purpose of this study was …
to sustain tumor growth and to resist conventional therapies. The purpose of this study was …
[HTML][HTML] S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
…, S Maïga, JM Henlin, F Colland, L Kraus-Berthier… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Escape from apoptosis is one of the major hallmarks of cancer cells. The B-cell Lymphoma
2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key …
2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key …
Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors
N Guilbaud, L Kraus-Berthier, F Meyer-Losic… - Clinical Cancer …, 2001 - AACR
S 23906-1 is a novel acronycine derivative selected on the basis of its potency in vitro. We
investigated the antitumor activity of S 23906-1 against several murine transplantable tumors (…
investigated the antitumor activity of S 23906-1 against several murine transplantable tumors (…
Synthesis and cytotoxic and antitumor activity of esters in the 1, 2-dihydroxy-1, 2-dihydroacronycine series
…, N Guilbaud, S Léonce, L Kraus-Berthier… - Journal of medicinal …, 1996 - ACS Publications
Seven 1,2-dihydroxy-1,2-dihydroacronycine and 1,2-dihydroxy-1,2-dihydro-6-demethoxyacronycine
esters and diesters were synthesized via osmic oxidation of acronycine or 6-…
esters and diesters were synthesized via osmic oxidation of acronycine or 6-…
[HTML][HTML] Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
…, M Schoumacher, S Banquet, L Kraus-Berthier… - …, 2020 - ncbi.nlm.nih.gov
Apoptotic evasion has been postulated as one of the main mechanisms of multiple myeloma
(MM) cell survival. 1, 2 The intrinsic apoptotic pathway, tightly regulated by the BCL-2 …
(MM) cell survival. 1, 2 The intrinsic apoptotic pathway, tightly regulated by the BCL-2 …
Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents
V Lisowski, S Léonce, L Kraus-Berthier… - Journal of medicinal …, 2004 - ACS Publications
Herein, we describe the structure−activity relationship study of a new 3-aryl-8H-thieno[2,3-b]pyrrolizin-8-one
series of antitubulin agents. The pharmacological results from the National …
series of antitubulin agents. The pharmacological results from the National …
Ex vivo differentiated endothelial and smooth muscle cells from human cord blood progenitors home to the angiogenic tumor vasculature
…, J Contreres, B Boval, L Kraus-Berthier… - Cardiovascular …, 2004 - academic.oup.com
Objectives: Recent studies have provided increasing evidence that postnatal neovascularization
does not rely exclusively on sprouting of preexisting vessels, but also involves bone …
does not rely exclusively on sprouting of preexisting vessels, but also involves bone …
Synthesis of 9-O-Substituted Derivatives of 9-Hydroxy-5,6-dimethyl-6H- pyrido[4,3-b]carbazole-1-carboxylic Acid (2-(Dimethylamino)ethyl)amide and Their 10- and …
…, Y Charton, N Guilbaud, L Kraus-Berthier… - Journal of medicinal …, 1999 - ACS Publications
Analogues of the antitumor drug S 16020-2 modified at the 9, 10, or 11 position were synthesized
and evaluated in vitro and in vivo on the P388 leukemia and B16 melanoma models. …
and evaluated in vitro and in vivo on the P388 leukemia and B16 melanoma models. …
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL
…, S Banquet, AL Maragno, L Kraus-Berthier… - Blood …, 2020 - ashpublications.org
Improving survival outcomes in adult B-cell acute lymphoblastic leukemia (B-ALL) remains
a clinical challenge. Relapsed disease has a poor prognosis despite the use of tyrosine …
a clinical challenge. Relapsed disease has a poor prognosis despite the use of tyrosine …